Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis

NCT07686042 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07686042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
June 24, 2026
Completion date
December 31, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune cerebellitis, autoimmune encephalitis (ae)